{
    "clinical_study": {
        "@rank": "45380", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: ACP-196 50mg BID", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 1: ACP-196 50mg BID"
            }, 
            {
                "arm_group_label": "Cohort 2: ACP-196 100mg QD", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 2: ACP-196 100mg QD"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is evaluating two dosing regimens, the safety, and efficacy of a new Bruton\n      tyrosine kinase (Btk) inhibitor, ACP-196, for the treatment of subjects with Relapsed or\n      Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma."
        }, 
        "brief_title": "ACP-196, a Btk Inhibitor, for Treatment of Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma", 
        "condition": "Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women \u2265 18 years of age.\n\n          -  Pathologically confirmed de novo ABC DLBCL\n\n          -  Relapsed or refractory disease\n\n          -  Subjects must have \u2265 1 measurable disease sites\n\n        Exclusion Criteria:\n\n          -  A life-threatening illness, medical condition or organ system dysfunction which, in\n             the investigator's opinion, could compromise the subject's safety, interfere with the\n             absorption or metabolism of ACP-196, or put the study outcomes at undue risk\n\n          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,\n             congestive heart failure, or myocardial infarction within 6 months of screening, or\n             any Class 3 or 4 cardiac disease as defined by the New York Heart Association\n             Functional Classification, or LVEF < 40%\n\n          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or\n             resection of the stomach or small bowel or ulcerative colitis, symptomatic\n             inflammatory bowel disease, or partial or complete bowel obstruction.\n\n          -  Lactating or pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112526", 
            "org_study_id": "ACE-LY-002"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1: ACP-196 50mg BID", 
                "Cohort 2: ACP-196 100mg QD"
            ], 
            "intervention_name": "ACP-196", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma", 
            "Diffuse Large B-Cell Lymphoma", 
            "Novo Activated B-cell (ABC)", 
            "Novo Activated B-cell", 
            "ABC DLBCL", 
            "DLBCL", 
            "Lymphoma", 
            "B-Cell", 
            "Immunoproliferative Disorders", 
            "Immune System Diseases"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cologne", 
                        "country": "Germany"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plymouth", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b, Multicenter, Open-label Study of 2 Dosing Regimens of ACP-196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma", 
        "overall_contact": {
            "email": "s.rodriguez@acerta-pharma.com", 
            "last_name": "Sara Rodriguez, MHA", 
            "phone": "+1-650-591-4024"
        }, 
        "overall_official": {
            "affiliation": "Medical Monitor", 
            "last_name": "Ahmed Hamdy, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective Response", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112526"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Acerta Pharma BV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acerta Pharma BV", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Intervention Model: Parallel Assignment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}